According to media reports, on April 12, Innovative recombinant vaccine products developed by the team of academicians Chen Wei of the Chinese Academy of Engineering and Research Institute of Military Medicine of the Academy of Military Sciences
It is reported thatAbout 500 volunteers were vaccinated, including an 84 year old.
In the previous phase I clinical trial, the first batch of volunteers were observed in isolation, while in the phase II clinical trial,After vaccination, volunteers can go home to stayIt's not so different from daily vaccination.
Of course, during this period, the research group will send a special person for follow-up, and guide the completion of safety observation and records.
Recombinant new coronavirus (adenovirus vector) vaccine is the first new coronavirus vaccine to enter the clinical trial stage in the world. On March 17, phase I clinical trial began, 108 volunteers were recruited, divided into three groups: low dose, medium dose and high dose.
Among them,Academician Chen Wei has given his first shot of vaccine.
According to the statistics of who, there are 51 candidate new crown vaccines in the world at present. After the outbreak of the epidemic, China has simultaneously selected five technical routes to develop new crown vaccines, namely, inactivated vaccines, gene engineering recombinant subunit vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines, nucleic acid vaccines, covering the main categories of new crown vaccines in the world Type.
At present, Sinopharm Wuhan Institute of Biological Products Co., LtdNovel coronavirus (COVID-19) inactivated vaccine (Vero cell) I/II phase clinical trial, at the China Clinical Trial Registry
If all goes well, it will be the third new crown vaccine in the world to enter clinical trials after the recombinant new crown virus (adenovirus vector) vaccine of academician Chen Wei's team and the mRNA vaccine developed by Moderna, an American biotechnology company.